New chemotherapeutics strategies for the treatment of indolent lymphoid malignancies.
During the past few decades, clinical trials in indolent lymphoid malignancies have focused to a large extent on comparisons of combinations and permutations of conventional drugs, including alkylating agents and anthracyclines. Despite an enormous expenditure of financial and patient resources, there has been no major impact on survival, and these tumors remain incurable. Innovative approaches are clearly needed, including the development of new and more effective agents.
Cheson
B D
BD
Medicine Section, Clinical Investigations Branch, National Cancer Institute, Bethesda, MD 20892, USA.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology*; D005544:Forecasting; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans
D000970:Antineoplastic Agents